In this article, we will take a look at some of the best growth stocks under $100 to buy now.
Even if asked by a layman where they would want to invest, the answer would be straight: growth stocks. A growth stock comes from companies that have expanding revenues, disruptive ideas, and outperform potential.
Over the years, Warren Buffett has shifted from being a value investor to a quality investor. He now realizes that higher long-term returns from high-quality companies can be generated even at higher valuations than value stocks. Additionally, Buffett’s long-term investment horizon has played a significant role in his successful investing tenure. As he says,
“Our favorite holding period is forever.”
Thus, this analysis is based on stocks that have prices lower than $100 but have high long-term potential. These companies, from biopharmaceutical to fashion, have one thing in common: a strategy for the long haul. Despite short-term fluctuations, high-growth stocks possess a clear path to expansion, innovation, and market leadership.
A Wall Street trading desk monitoring the performance of large-cap growth stocks.
Our Methodology
In our analysis, we have incorporated stocks under $100 that have high growth potential. Using the Finviz screener, the stocks are filtered according to their price targets and analysts’ ratings. The stocks have been ranked according to the price target upside potential, based on the Yahoo Finance estimates, from the lowest to the highest.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
10. Urban Outfitters, Inc. (NASDAQ:URBN)
Upside potential as of June 11, 2025: 2.77%
Mark Altschwager, an analyst at Baird, raised the price target for Urban Outfitters, Inc. (NASDAQ:URBN) to $90 from $75, while elevating the rating from “Neutral” to “Outperform”. This price appreciation of 20% underscores the company’s position for a turnaround.
The company recently reported strong first-quarter results, with a 74% increase in net income stemming from margin improvement. The investors are closely monitoring the giant’s subscription/rental business, Nuuly, which is anticipated to grow 43% to $540m this year.
To sum it up, Urban Outfitters, Inc. (NASDAQ:URBN) is a unique “growth at a reasonable price” stock that is witnessing strong comp sales growth in each of its brands, and with even more room to grow via both price hikes and traffic increases. As long as the company is able to capitalize on Nuuly, we can expect it to show sustained momentum.
Urban Outfitters, Inc. (NASDAQ:URBN) is a Pennsylvania-based fashion business that operates through three segments: Retail, Wholesale, and Subscription. Incepted in 1970, the company serves its customers directly through websites and retail stores, as well as social media and external sources. While the broader market delivered nearly 100% return in five years, URBN has exhibited a return of 295%.
9. Verona Pharma plc (NASDAQ:VRNA)
Upside potential as of June 11, 2025: 7.8%
Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from $95, with an unchanged “Buy” rating. This was after the successful launch of the COPD treatment Ohtuvayre, which has witnessed strong sales growth.
During the first quarter, Ohtuvayre delivered $71 million in sales, reflecting an increase of nearly 90% from the previously reported 37 million in the last quarter. Verona Pharma plc (NASDAQ:VRNA) continues to capitalize on this growing demand, with peak sales projections between $3 billion and $5 billion. As the numbers suggest, this is anything but ordinary. The optimism surrounding the company’s profitability in the second quarter is just the cherry on top.
Some believe that Verona Pharma plc (NASDAQ:VRNA) is heading north to be the next big franchise. With its potential, Wall Street anticipates the giant to achieve $1 billion in sales by 2028, driven by its safety profile, global expansion, robust patent protection, and an underserved market of 398 million people with COPD.
Verona Pharma plc (NASDAQ:VRNA) is a London-based biopharmaceutical company that develops and markets therapies for treating patients suffering from respiratory diseases. Incorporated in 2005, the company is committed to improving the lives of many by offering innovative drugs.
